Decisions 10th April 2018


At the meeting that took place on 10th April, the following decisions were agreed.

New Drug Requests

Approved

Fobumix Easyhaler® (budesonide/formoterol)

  • Approved for inclusion onto the formulary for asthma and COPD.  DuoResp Spiromax® to be made non-formulary.

Not Approved

Apixaban

  • Not approved for inclusion onto the formulary for patients undergoing mitral valve repairs and tissue mitral valve replacements.


Shared Care Protocols/TLS Change in Status

Dymista Nasal Spray  (TLS amber to green)

  • The extra evidence provided was discussed and it was concluded it did not demostrate dymista nasal spray to be more effective than other sprays on the formulary or reduce referrals. To remain TLS amber.

Quinagolide (TLS red to amber)

  • Change of TLS from red to amber 3 months agreed

Testosterone undecanoate (Nebido) and testosterone decanoate, isocaproate, phenylpropionate and propionate (Sustanon)

  • New SCPs, clarification of time frame for measuring testosterone levels required

Azathioprine

  • Updated SCP and advise sheet approved

Hydroxychloroquine

  • Updated SCP and advise sheet approved

Riluzole

  • Updated SCP approved

Modafinil (TLS red to amber)

  • Change of TLS from red to amber 3 months, SCP agreed

Levodopa,carbidopa and entacapone combined tablet

  • Updated SCP approved

Entacapone

  • Updated SCP approved

 

Other

Fiasp

  • The JFG agreed the use of fiasp for patients requiring multiple injections where post-prandial hyperglycaemia is a particular problem.

Last updated by: Tash Mogford on 21-05-2018 13:56